123i- metaiodobenzylguanidine in chronic heart failure: is there a clinical use?

Nuclear Medicine Communications

Volumn 27, Issue 12, 2006, Pages 927-931

  Motherwell, Duncan W ^a   Petrie, Mark C ^a   Martin, William ^a   Cobbe, Stuart M ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

ADRENERGIC SYSTEM; DRUG UPTAKE; EDITORIAL; HEART FAILURE; HUMAN; IMAGING;

3-IODOBENZYLGUANIDINE; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; METABOLIC CLEARANCE RATE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33750719630     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000251331.48203.74     Document Type: Editorial

References (34)

1. Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthorne NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981; 22:22-31.
2. Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992; 33:471-477.
3. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;:9-13.
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;:2001-2007.
5. Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group. Am J Cardiol 1992; 69:103-107.
6. Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue P, Shinohara S. Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986; 27:84-89.
7. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, Fukuyama T. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995; 26:1594-1599.
8. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril. Eur J Nucl Med Mol Imaging 2005; 32:964-971.
9. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997; 38:1085-1089.
10. Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun 1999; 20:529-535.
11. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12:1252-1258.
12. Dae MW, De Marco T, Botvinick EH, O’Connell JW, Hattner RS, Huberty JP, Yuen-Green MS. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies. J Nucl Med 1992; 33:1444-1450.
13. Kobayashi H, Momose M, Kanaya S, Kondo C, Kusakabe K, Mitsuhashi N. Scatter correction by two-window method standardizes cardiac I-123 MIBG uptake in various gamma camera systems. Ann Nucl Med 2003; 17:309-313.
14. Small AD, Prosser J, Motherwell DW, McCurrach GM, Fletcher AM, Martin W. Downscatter correction and choice of collimator in 123 I imaging. Phys Med Biol 2006; 51:N307-N311.
15. Merlet P, Pouillart F, Dubois-Rande JL, Delahaye N, Fumey R, Castaigne A, Syrota A. Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. J Nucl Med 1999; 40:224-231.
16. Lotze U, Kober A, Kaepplinger S, Neubauer S, Gottschild D, Figulla HR. Cardiac sympathetic activity as measured by myocardial 123-I-metaiodobenzylguanidine uptake and heart rate variability in idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83:1548-1551.
17. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril. Eur J Nucl Med Mol Imaging 2005; 32:964-971.
18. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002; 43:1279-1285.
19. Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997; 38:1085-1089.
20. Gerson MC, Craft LL, McGuire N, Suresh DP, Abraham WT, Wagoner LE. Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 2002; 9:608-615.
21. Erol-Yilmaz A, Verberne HJ, Schrama TA, Hrudova J, De Winter RJ, Eck-Smit BL, et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol 2005; 28:304-310.
22. Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, Adachi I, Narabayashi I. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997; 133:353-358.
23. de Milliano PA, Tijssen JG, Eck-Smit BL, Lie KI. Cardiac 123 I-MIBG imaging and clinical variables in risk stratification in patients with heart failure treated with beta blockers. Nucl Med Commun 2002; 23:513-519.
24. Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, Nakano H, Yamazaki J. Usefulness of meta-[123I]iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nucl Med Commun 2005; 26:97-102.
25. Klein H, Auricchio A, Reek S, Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999; 83:91D-97D.
26. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
27. Schwartz PJ, Randall WC, Anderson EA, Engel BT, Friedman M, Hartley LH, et al. Sudden cardiac death. Nonpharmacologic interventions. Circulation 1987; 76:I215-I219.
28. Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003; 10:121-131.
29. Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999; 33:759-766.
30. Ogita H, Shimongata T, Fukunami M, Kumagai K, Yamada T, Asano Y et al. Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity inpatients with chronic heart failure: a prospective study. Heart 2001; 86:656-660.
31. Ebina T, Takahashi N, Mitani I, Sumita S, Ishigami T, Ashino K et al. Clinical implications of cardiac 1231-metaiodobenzylguanidine scintigraphy and cardiac natriuretic peptides in patients with heart disease. Nucl Med Cummun 2002; 23:795-801.
32. Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by 1-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 2003; 384-391.
33. Yamada T, Shiraongata T, Fukunami M, Kumagai K, Ogita H, Hirata A et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. J Am Coll Cardiol 2003; 41:231-238.
34. Anastasiou-Nana MI, Tcrrovitis JV, Athanasoulis T, Karaloizos L, Geramoutsos A, Pappa L et al. Prognostic value of iodine-123-metaiodobenzylguanidine myocardial uptake and heart rate variability in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2005; 96:427-431.